LYNTONIX participated in the 2026 BioMed-X Biomedical Startup Matchmaking Expo, held on August 5–6, 2026, and organized by the Taoyuan City Government and the Industrial Technology Research Institute (ITRI). During the event, LYNTONIX engaged in one-on-one matchmaking and discussions with experts across a wide range of fields, including investment, manufacturing, clinical application, and regulatory affairs. LTX-568, LYNTONIX’s lead drug candidate, received highly positive feedback and strong interest from industry representatives and venture capital investors.
LYNTONIX also participated in the event’s Gold Mining Competition – Poster Evaluation, where a panel of industry experts assessed participating startups based on criteria including technological innovation, unmet market needs, commercialization potential, and team capabilities and resources. LYNTONIX distinguished itself from more than 200 participating companies and advanced to the final eight, earning a place in the 3-Minute Elevator Pitch final. Following the final presentation, LYNTONIX received strong recognition from multiple industry judges and was selected as a Merit Award winner in the Smart Healthcare Category.
LTX-568 is a novel, non-addictive small-molecule analgesic being developed for the treatment of chronic abdominal pain associated with irritable bowel syndrome (IBS). Despite the significant burden of abdominal pain in IBS, effective treatment remains a major unmet medical need, largely due to the complex and incompletely understood pathophysiology of IBS and the lack of well-validated therapeutic targets.
The LYNTONIX team identified a novel therapeutic target that is highly expressed in intestinal mucosal samples from patients with IBS and subsequently developed LTX-568 to selectively target this pathway. LTX-568 is designed to offer key advantages, including scalability for manufacturing, high target selectivity, long-lasting therapeutic effects, and a favorable safety profile.
LTX-568 is now approaching the GLP toxicology study stage, a key milestone in its preclinical development. LYNTONIX plans to submit Investigational New Drug (IND) applications in the United States and Taiwan in 2028, paving the way for LTX-568 to advance into human clinical development.LYNTONIX, INC.－Yvonne Lin－3-minute elevator pitch (second from the right)From left to right：ITRI－Maggie Lu. | LYNTONIX, INC.－Miranda Lee, Dr. Jack Hsin (Founder), Yvonne Lin, Dr. Karen Chang.https://www.lyntonix.com/en/hot_539349.html[2026/08] Awards－LYNTONIX Wins the Merit Award in the Smart Healthcare Category at the 2026 BioMed-X Startup Competition, with LTX-568 Earning Broad Recognition2026-09-112027-09-11
This year, LYNTONIX made its first appearance at BIO Asia, where the company presented its latest R&D progress and introduced its lead product candidate, LTX-568.
LTX-568 is a first-in-class small-molecule drug candidate that selectively targets the serotonin 7 receptor (5-HT7 receptor) in intestinal tissues. It is being developed to address the long-standing unmet medical need for chronic abdominal pain in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). LTX-568 is differentiated by its potential to provide safe and effective pain relief with a low risk of adverse effects and, importantly, without the risk of addiction.
During BIO Asia, LYNTONIX actively engaged with potential international strategic partners, including venture capital investors, CMC manufacturers, and biotechnology companies. The company has now formally initiated its fundraising efforts to advance LTX-568 into the next stage of development.
Laboratory-scale production of LTX-568 at the tens-of-grams scale has been completed, and the program is now preparing to advance to kilogram-scale active pharmaceutical ingredient (API) manufacturing. Lyntonix also plans to initiate GLP toxicology studies, representing a critical final step toward IND submission. The company aims to file IND applications in both the United States and Taiwan, laying the foundation for LTX-568 to enter first-in-human clinical trials.https://www.lyntonix.com/en/hot_539348.html[2026/07] News－LYNTONIX Debuts at BIO Asia, highlights LTX-568 development progress and pursues global strategic partnerships2026-09-112027-09-11
In April 2026, the registration of the capital increase through technology shares was officially completed, making NTU and the NTU investors shareholders of LYNTONIX.https://www.lyntonix.com/en/hot_539347.html[2026/04] News－LYNTONIX Secured exclusive technology License from National Taiwan University (NTU).2026-09-112027-09-11
LYNTONIX was awarded the "2025 National Innovation Excellence Award" by the Biotechnology and Medical Technology Policy Research Center Foundation, recognizing LYNTONIX's achievements and results in core technologies, commercial applications, and intellectual property patent layout.According to research findings, oral administration of LTX-568 for 30 min significantly relieved visceral pain in irritable bowel syndrome (IBS) animal models compared to existing IBS drugs. Moreover, after 10 consecutive days of treatment, the abnormal proliferation of nerve fibers in intestinal mucosal layer and the overexpression of serotonin 7 receptor were back to normal levels. These findings have been published in academic journals.
In 2024 and 2025, LTX-568 was granted the patents in Europe and China, respectively. Together with the existing patents in United States, Japan, South Korea, and Taiwan, the patent portfolio covers the major IBS pharmaceutical markets worldwide. In 2025, LYNTONIX was established, and the licensing of LTX-568 was successfully completed.
Click here to open news linkhttps://www.lyntonix.com/en/hot_526939.html[2025/12] Award－LYNTONIX won the 2025 Innovative Improvement Award2026-09-112027-09-11
According to Article 3, Paragraph 1 of “Regulations Governing the Identification of High-Risk Innovative Startups as Referred to in Article 12 of the Income Basic Tax Act”, LYNTONIX has been approved as a “High-Risk Innovative Startup”. Investments in LYNTONIX are therefore eligible for the Income Basic Tax credit.https://www.lyntonix.com/en/hot_522358.html[2025/03] News－ LYNTONIX has been approved as a High-Risk Innovative Starup by Industrial Development Administration (IDA), Ministry of Economic Affairs (MOEA), Taiwan2026-09-112027-09-11
LYNTONIX attended 2025 BIO Asia and showcased the latest research data on LTX-568. During the convention, LTX-568 received strong interest and highly positive feedback from industry experts and partners. The next step for LTX-568 is to complete the GLP preclinical studies, and advance to clinical trials. Our mission is clear：Let the IBS patients regain control of their lives. LYNTONIX will keep focusing on the effective and safe thetreatment of IBS abdominal pain.https://www.lyntonix.com/en/hot_522357.html[2025/07] Exhibition announcement－ LYNTONIX promoted LTX-568 in 2025 BIO Aisa2026-09-112027-09-11
LYNTONIX was honored to be one of the Taiwanese biomedical startup companies selected by NSTC to participate in 2025 US BIO, promoting our innovatice product, LTX-568. During the convention, LTX-568 attracted strong interest and received highly positive feedback from industry experts and global partners. We look forward to advancing LTX-568 into clinical studies, and conquering the unmet needs for IBS abdominal pain.https://www.lyntonix.com/en/hot_522356.html[2025/06] Exhibition announcement－ LTX-568 draws global attention at the 2025 BIO International Convention2026-09-112027-09-11
BIO2025 Exhibitor Directory
https://bio2025.mapyourshow.com/8_0/exhibitor/exhibitor-details.cfm?exhid=00953459https://www.lyntonix.com/en/hot_516190.html[2025/06] Exhibition announcement－ LYNTONIX will participate in the US BIO 20252026-09-112027-09-11
LYNTONIX successfully completed company registration on March 25, 2025.https://www.lyntonix.com/en/hot_516388.html[2025/03] News－ LYNTONIX has Completed the Company Registration2026-09-112027-09-11
國科會「創新創業激勵計畫」 113年第二梯次決選暨頒獎典禮 (2024.11.29) : News link
竹科輔導4組FITI計畫團隊績效完勝 年終再獲傑出獎及潛力獎(2024.11.29): News link
臺大藥刊 第086期 專題報導－徹底翻轉我們的創新創業激勵計劃 (2025.03.25) :News link
臺大校訊 1461期－臺大腸躁症新藥團隊獲得FITI競賽創業傑出獎 (2025.04.10) :News link https://www.lyntonix.com/en/hot_516193.html[2024/11] News－ LYNTONIX has won the biggest award at the 2024 FITI2026-09-112027-09-11
10th Annual SPARK Global Meeting (2024.9/20) https://sparkglobal.io/10th-annual-spark-global-meeting/
科政團隊赴美參加2024 SPARK VC Day 協助新創技術募資及產業交流 (2024.11.30) https://www.stpi.niar.org.tw/news/detail/9a243d26-8dd2-4f69-9c25-cc32fdbacb77https://www.lyntonix.com/en/hot_516189.html[2024/09] News－ LYNTONIX was invited to participate in the 2024 SPARK VC DAY at Stanford University2026-09-112027-09-11
https://innoaward.taiwan-healthcare.org/award_detail.php?REFDOCTYPID=0r4ggllnka0x43sh&num=1&REFDOCID=0q2p6w3o3k3zpccohttps://www.lyntonix.com/en/hot_516192.html[2023/11] Award－ LYNTONIX won the 2023 Innovative Improvement Award2026-09-112027-09-11
https://innoaward.taiwan-healthcare.org/award_detail.php?REFDOCID=0q2p6w3o3k3zpccohttps://www.lyntonix.com/en/hot_516386.html[2019/12] Award－ LYNTONIX won 16th National Innovation Award2026-09-112027-09-11
